Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Deficient Solid Tumors”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Testing effectiveness (Phase 2)UnknownNCT04983745
What this trial is testing

Niraparib and Dostarlimab in HRD Solid Tumors

Who this might be right for
Homologous Recombination Deficient Solid Tumors
West Cancer Center 30
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Early research (Phase 1)Study completedNCT01017640
What this trial is testing

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Who this might be right for
Solid Neoplasm
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)Study completedNCT04123366
What this trial is testing

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Who this might be right for
Solid Tumors
Merck Sharp & Dohme LLC 333
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 329
Testing effectiveness (Phase 2)Study completedNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT05038839
What this trial is testing

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
M.D. Anderson Cancer Center 44
Early research (Phase 1)Active Not RecruitingNCT00777582
What this trial is testing

Phase I Comparative Bioavailability Study

Who this might be right for
Solid Tumors
AstraZeneca 197
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06237205
What this trial is testing

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Who this might be right for
Efficacy
Korea University Anam Hospital 33
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Testing effectiveness (Phase 2)Looking for participantsNCT07446855
What this trial is testing

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 180
Early research (Phase 1)Looking for participantsNCT06545942
What this trial is testing

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more
MOMA Therapeutics 220
Testing effectiveness (Phase 2)Study completedNCT03274661
What this trial is testing

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Who this might be right for
Solid Tumor, Adult
Baptist Health South Florida 52
Testing effectiveness (Phase 2)Ended earlyNCT05126433
What this trial is testing

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorUrothelial Cancer+2 more
Jazz Pharmaceuticals 47
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT04174716
What this trial is testing

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)

Who this might be right for
Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
Idience Co., Ltd. 108
Early research (Phase 1)Ended earlyNCT03209401
What this trial is testing

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Who this might be right for
Solid Tumor, AdultHomologous Recombination Deficiency
Georgetown University 23
Next Page